PILA PHARMA AB Logo

PILA PHARMA AB

Clinical-stage biopharma developing a first-in-class oral drug for diabetes and obesity.

PILA | ST

Overview

Corporate Details

ISIN(s):
SE0015988274
LEI:
6488Z7WG18Q0ZN0V0262
Country:
Sweden
Address:
Norra Vallgatan 72, 211 22 Malmö
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

PILA PHARMA AB is a clinical-stage biopharmaceutical company focused on developing a potential first-in-class oral treatment for metabolic diseases, primarily type 2 diabetes and obesity. The company's lead candidate, XEN-D0501, is a TRPV1 antagonist, representing a novel therapeutic approach with a different mechanism of action compared to mainstream treatments. The company's strategy emphasizes the development of a convenient oral tablet to address the large global patient population. PILA PHARMA is actively advancing its clinical program, with a recent strategic focus on dedicated obesity studies aimed at generating a comprehensive data package to facilitate future partnerships.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PILA PHARMA AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PILA PHARMA AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PILA PHARMA AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Israel
TMIS
THERACRYF PLC Logo
Developing sulforaphane-based therapeutics for oncology and behavioural brain disorders.
United Kingdom
TCF
Toleranzia AB Logo
Developing immune therapies for rare autoimmune diseases like myasthenia gravis.
Sweden
TOL
UCAR Logo
A nonprofit consortium managing atmospheric research and providing resources to the scientific community.
France
ALUCR
VERICI DX PLC Logo
AI-powered diagnostic tests for the kidney transplant market, predicting organ rejection and injury.
United Kingdom
VRCI
Vicore Pharma Holding Logo
Develops AT2 receptor drugs and a digital therapeutic for pulmonary fibrosis.
Sweden
VICO
R&D in renewable energy & manufacturing specialized tools for automotive & engineering.
Slovakia
0OCW
Xlife Sciences AG Logo
A life sciences incubator commercializing early-stage academic research for healthcare markets.
Switzerland
XLS
Yoshi Innovation Spolka Akcyjna Logo
A tech fund incubating MedTech, biotech, and defense ventures with investment and IP protection.
Poland
YOS

Talk to a Data Expert

Have a question? We'll get back to you promptly.